ImmunoCellular Therapeutics Ltd (IMUC PINK) stock market data APIs
$0.103
0(0%)
as of June 30, 2025
Try our APIs with
free plan!
ImmunoCellular Therapeutics Ltd Financial Data Overview
Price chart is built with
Anychart
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
Prev. Close
0.103
Open
0.103
High
0.103
Low
0.103
52 wk Range
0.061-0.205
Market Cap
13 258 K
P/E Ratio
0.0186
Shares Outstanding
127 M
EPS
0
Beta
0.834
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ImmunoCellular Therapeutics Ltd data using free add-ons & libraries
Get ImmunoCellular Therapeutics Ltd Fundamental Data
ImmunoCellular Therapeutics Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -6 072 270
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-05-14
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ImmunoCellular Therapeutics Ltd News
New
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
Codexis, Inc. REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the...
ImmunoCellular Therapeutics: Notice of Proposed Settlement of Derivative Action
LOS ANGELES, Aug. 09, 2019 (GLOBE NEWSWIRE) -- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC), today issued the following announcement. The following is being released pursuan...
New Research Coverage Highlights K12, ImmunoCellular Therapeutics, The First of Long Island, Blue Bird, The Providence Service, and German American — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders,...
Research Report Identifies Gastar Exploration, Monroe Capital, SandRidge Energy, ImmunoCellular Therapeutics, Inseego, and Digital Turbine with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
